Liposomal siRNA nanocarriers for cancer therapy.
暂无分享,去创建一个
[1] Y. Maitani,et al. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[2] C. Ehrhardt,et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] J. Burnett,et al. RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.
[4] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[5] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[6] Yuhan Lee,et al. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. , 2008, Molecular pharmaceutics.
[7] G. Wnek,et al. The use of progenitor cell/biodegradable MMP2-PLGA polymer constructs to enhance cellular integration and retinal repopulation. , 2010, Biomaterials.
[8] P. Linsley,et al. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.
[9] N. Phillips,et al. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.
[10] Jinwoo Cheon,et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. , 2009, Angewandte Chemie.
[11] Jing Qin,et al. Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. , 2007, Chemical & pharmaceutical bulletin.
[12] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[13] Shubiao Zhang,et al. Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[14] S. Hammond,et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.
[15] N. Phillips,et al. Major limitations in the use of cationic liposomes for DNA delivery , 1998 .
[16] N. Kosaka,et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.
[17] Robert J. Lee,et al. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. , 2003, Anticancer research.
[18] T. Park,et al. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. , 2006, Bioconjugate chemistry.
[19] A. Sood,et al. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors , 2012, Clinical Cancer Research.
[20] L. Ellis,et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.
[21] N. Svrzikapa,et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.
[22] A. Sood,et al. Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.
[23] A. Sood,et al. Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.
[24] Prahlad T. Ram,et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. , 2011, Journal of the National Cancer Institute.
[25] Andrew D. Miller,et al. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.
[26] Yang Wang,et al. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[27] A. Sood,et al. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer , 2013, Molecular therapy. Nucleic acids.
[28] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[29] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[30] Y. Rojanasakul,et al. Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.
[31] Mark E. Davis,et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.
[32] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.
[33] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[34] Liz Y. Han,et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.
[35] Jan-Fang Cheng,et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.
[36] A. Sood,et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.
[37] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[38] M. Stoffel,et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.
[39] J. Burnett,et al. Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges , 2013, Pharmaceuticals.
[40] P. Low,et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. , 2008, Gynecologic oncology.
[41] Jörg Huwyler,et al. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. , 2004, Journal of the National Cancer Institute.
[42] C. Miller,et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.
[43] Dan Peer,et al. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.
[44] Liz Y. Han,et al. Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.
[45] Shan Jiang,et al. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.
[46] A. C. Hunter,et al. Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[47] Y. Hashimoto,et al. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. , 1997, British Journal of Cancer.
[48] G. Hannon,et al. Unlocking the potential of the human genome with RNA interference , 2004, Nature.
[49] B. Ozpolat,et al. Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines. , 2003, Methods in enzymology.
[50] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[51] Anil K Sood,et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.
[52] E. Fattal,et al. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. , 2006, Advanced drug delivery reviews.